The authors would like to thank L. Pieters, T. Thiron, and G. De Smet for their technical support. We are thankful to all the volunteers who donated blood for the study. The work was financially supported by the Research Foundation- Flanders (FWO) under Grant (T000118N).

For this study, blood samples were collected by venipuncture from 30 healthy donors aged between 17 and 65 years. MN data from 20 donors were reused from the paper of Beyls et al.8 Collection of the blood samples is in accordance with the guidelines of the Ethics Committee of Ghent University Hospital (registration number:2019/1565), Belgium. Written informed consent was obtained from all the participants. See the Table of Materials for details related to all materials and reagents used in this protocol.
1.&#160;Collection of blood samples
<ol>
	<li>Before starting, ensure that written informed consent of the participants is available and ethical guidelines are followed properly .</li>
	<li>Collect blood into Li-Heparin tubes and store at room temperature until ready for processing for cryopreservation.</li>
</ol>
2.&#160;Cryopreservation of whole blood
NOTE: All the steps until cell harvesting are performed aseptically in sterile laminar airflow.
<ol>
	<li>To cryopreserve 1 mL of blood, make 1 mL of freezing medium by mixing 800 &#181;L of Fetal Calf Serum (FCS) and 200 &#181;L of dimethyl sulfoxide (DMSO). 
	NOTE: The freezing medium is prepared in a volume equal to the blood samples that need to be frozen.</li>
	<li>For cryopreservation of whole blood, transfer the blood sample from the heparinized tube to 15 or 50 mL centrifuge tubes 
	NOTE: The capacity of the tube depends on the volume of the blood.</li>
	<li>Vortex the blood at low speed with continuous but dropwise addition of an equal volume of freezing medium.</li>
	<li>Transfer 2 mL of blood-freeze mix into cryovials (2 mL) where each aliquot has 1 mL of blood sample mixed with 1 mL of freezing mixture.</li>
	<li>Stepwise gradual freezing
	<ol>
		<li>Transfer cryovials to a cryobox containing isopropanol and put in a&#160;freezer&#160;(-80 &#176;C) for overnight.</li>
		<li>Transfer the cryovials to liquid nitrogen for long-term use.</li>
	</ol>
	</li>
</ol>
3.&#160;Thawing of cryopreserved blood
NOTE: To limit the total time of the thawing process, a maximum of 8 cryovials (2 mL each) should be handled at a time.
<ol>
	<li>Preparation
	<ol>
		<li>Prewarm 200 mL of sterile Phosphate-buffered Saline (PBS) to 37 &#176;C before thawing the blood.</li>
		<li>Prepare a working solution of the required culture medium under sterile conditions. Ensure that medium per culture includes 1.6 mL of complete medium: Rosewell Park Memorial Institute (RPMI) media supplemented with penicillin/streptomycin (0.5%), 0.2 mL of FCS, 20 &#181;L of sodium pyruvate, and 2 &#181;L of &#946;-mercaptoethanol. 
		NOTE: Since a significant number of blood cells can be lost while thawing, the thawed blood is cultured in small wells like 24-well plates with a total volume of 2 mL. One multi-well plate per dose is used.</li>
		<li>For each culture well, indicate the donor code and A/B on the lid along with the date and dose, as suggested below (Figure 1).</li>
	</ol>
	</li>
</ol>
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/65855/65855fig01.jpg" /> 
Figure 1: Suggested layout of a 24-well plate to culture whole blood for the micronucleus assay. Mark the wells and indicate the donor codes at appropriate places on the lid. For each patient sample, duplicate wells should be adjacent to each other. Note that it is a suggestive layout for a 10 x 10 collimator and can be changed according to the size of the collimator or samples. <a href="https://www.jove.com/files/ftp_upload/65855/65855fig01large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<ol start="2">
	<li>Steps for thawing and culturing whole blood
	<ol>
		<li>Warm the water bath to 37 &#176;C.</li>
		<li>Take out the required cryovials from the liquid nitrogen (the number depends on the requirements such as the number of doses). 
		&#8203;NOTE: One cryovial contains 1 mL of blood and 1 mL of freezing medium. Therefore, two cultures can be set up with blood from one cryovial.</li>
		<li>Partially thaw the cryovials in the warm water bath (until small ice crystals are still seen).</li>
		<li>Take out the vials from the water bath and clean the outside of the vials with sterile tissue paper.</li>
		<li>In a sterile laminar airflow hood , open the vials very slowly to prevent air bubbles formed inside the tubes from spilling out.</li>
		<li>Resuspend the contents of each vial and individually transfer them to a 15 mL conical centrifuge tube (1 tube per vial).</li>
		<li>To the respective tubes, add dropwise 1 mL of warm (37 &#176;C) PBS while gently swirling the tube. Resuspend with a P1000 pipette.</li>
		<li>For dilution and uniform washing, add dropwise 7 mL of prewarmed PBS (37 &#176;C) and resuspend with a P1000 pipette.</li>
		<li>Centrifuge the blood for 8 min at 180 &#215; g (with setting at acceleration 1, brake 1) at room temperature.</li>
		<li>During this waiting step, fill the empty wells (other than the one where cells will be cultured) with 500 &#181;L of PBS.</li>
		<li>Place the well plates back in the incubator to prewarm.</li>
		<li>Once the centrifugation is completed, carefully remove the supernatant, leaving behind approximately 1 mL to avoid disturbing the cell pellet.</li>
		<li>Resuspend the pellet in the remaining supernatant with a P1000 pipette.</li>
		<li>Add dropwise 8 mL of warm PBS (37 &#176;C) into the respective tubes while gently swirling the tubes. Afterwards, resuspend with a P1000 pipette.</li>
		<li>Centrifuge the resuspended blood for 8 min at 180 &#215; g (with setting at acceleration 9, brake 9).</li>
		<li>During this waiting step, transfer 200 &#181;L of culture medium to each of the marked wells.</li>
		<li>Keep the plates back in the incubator to remain at 37 &#176;C.</li>
		<li>After centrifugation, remove the supernatant in a continuous motion (to avoid disturbing the loose cell pellet), but leave behind approximately 80 &#181;L of the supernatant.</li>
		<li>To the pellet, add 280 &#181;L of FCS (room temperature) and resuspend (to a total volume of 360 &#181;L).</li>
		<li>Transfer 180 &#181;L of the cell suspension to each well and resuspend (= 0.5 mL of &#34;blood&#34;/culture). The total volume in each well is now 380 &#181;L, resulting in a 2 mm medium layer.</li>
		<li>Incubate the plates in a CO2 incubator at 37 &#176;C for at least 10 min before irradiation.</li>
	</ol>
	</li>
</ol>
4.&#160;G0 MN assay
<ol>
	<li>Take out the plates from the incubator and irradiate the cell culture with required doses such as 0.5,&#160;1, and 2 Gy X-rays (220 kV, 13 mA, 0.15 mm Cu) at room temperature. Use sham irradiated samples as controls to identify spontaneous MN yields.</li>
	<li>Immediately after irradiation, add 1.62 mL of culture medium (37 &#176;C) to each well.</li>
	<li>To stimulate cell division in T-lymphocytes, add 40 &#181;L of Phytohemagglutinin (PHA) to each well and resuspend thoroughly.</li>
	<li>Place these plates back in the incubator (5% CO2, 37 &#176;C). 
	NOTE: This will be the starting time of the assay.</li>
	<li>Block the cytokinesis 23 h post stimulation by adding 8 &#181;L of cytochalasin B (6 &#181;g/mL) per well and resuspend properly.</li>
	<li>Harvest the cell cultures 70 h post stimulation/culture time. Resuspend and transfer the cells to a 15 mL tube. Rinse each well with 2 mL of PBS and add this PBS to the respective 15 mL tube.</li>
	<li>Centrifuge the tubes for 8 min at 180 &#215; g, at room temperature.</li>
	<li>Discard the supernatant but leave approximately 500 &#181;L over the pellet.</li>
	<li>Vortex the pellet (at full speed) and while vortexing, slowly add dropwise 2 mL of cold potassium chloride (KCl, 4 &#176;C).</li>
	<li>Immediately centrifuge the cells at 180 &#215; g for 8 min.</li>
	<li>Discard the supernatant, leaving approximately 500 &#181;L of the supernatant.</li>
	<li>Vortex the pellet (at full speed) and while vortexing, slowly add dropwise 2 mL of cold fixative 1 (Methanol/Acetic acid/Ringer solution in a ratio of 4:1:5).</li>
	<li>Leave the sample tubes overnight at 4 &#176;C (minimum 12 h and maximum 96 h).</li>
	<li>Centrifuge for 8 min at 180 &#215; g.</li>
	<li>Discard the supernatant.</li>
	<li>Vortex the pellet (at full speed) and while vortexing, slowly add dropwise 2 mL of cold fixative 2 (methanol/acetic acid in a ratio of 4:1).</li>
	<li>Centrifuge for 8 min at 180 &#215; g.</li>
	<li>Discard the supernatant.</li>
	<li>Vortex the pellet (at full speed) and then add slowly (dropwise), while vortexing, 2 mL of cold fixative 2 to the pellet.</li>
	<li>Leave the sample tubes at 4 &#176;C (minimum 12 h and maximum 96 h).</li>
	<li>Clean the slides with isopropanol and label them properly. 
	NOTE: Use printed stickers to label as marker ink is easily wiped off while processing.</li>
	<li>Centrifuge the sample tubes for 8 min at 180 &#215; g.</li>
	<li>Transfer the supernatant to another tube to concentrate the cells according to the size of the pellet.</li>
	<li>Vortex the pellet.</li>
	<li>Drop 40 &#181;L of the fixed cells on a dry and clean slide.</li>
	<li>Let the slides dry at room temperature. Store the slides in a box or stain immediately for observation.</li>
</ol>
5.&#160;Acridine orange (AO) staining
<ol>
	<li>Immerse the slides in AO stain for 1 min, followed by a quick wash in the distilled water, and then, place the slides in phosphate buffer (pH 6.8) for 1 min.</li>
	<li>Take out the slides from the buffer solution and with clean tissue paper, dry the back of the slides, and put the slides on a clean tissue paper.</li>
	<li>Drop 20 &#181;L of the phosphate buffer on top of the slide and gently cover it with a clean coverslip, avoiding air bubbles.</li>
	<li>Seal these slides with silicone cement. 
	&#8203;NOTE: Since AO is light-sensitive and fades over time, for a nice contrast and fluorescence, scoring of the slides is recommended within 5 days of staining. Always store slides in a cold room (4 &#176;C), when not examined.</li>
</ol>
6.&#160;Scoring stained slides
<ol>
	<li>Place your slide under a fluorescence&#160;microscope and examine 1,000 binucleated cells (BNs). Manually count MNs, which are one of the six biomarkers of toxicity. To do so, have two independent scorers examine 500 BN cells/slide under the same magnification. 
	NOTE: Following are some highlights of the scoring criteria, as recommended by Fenech to score the&#160;stained slides9
	<ol>
		<li>Select a BN cell by looking for nicely rounded cells with intact cytoplasm, with two well-distinguished nuclei of approximately the same size, regular shape, and staining pattern. Ensure that the cytoplasm of the BN cell is distinguishable from the cytoplasm of the adjacent cell.</li>
		<li>Score a MN, noting that it is morphologically identical to but smaller than the main nuclei; even the largest MN cannot be more than 1/3&#160;of the diameter of the main nuclei. Score a&#160;MN only if it does not touch the main nuclei or at least the micronuclear boundary is distinguishable from the boundary of the main nuclei.</li>
	</ol>
	</li>
</ol>

Examining Micronuclei Yields in Irradiated Whole Blood Samples

<ol>
	<li>Grade, M., Difilippantonio, M. J., Camps, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Patterns+of+chromosomal+aberrations+in+solid+tumors.">Patterns of chromosomal aberrations in solid tumors.</a> Recent Results in Cancer Research. 200, 115-142 (2015).</li><li>Jiao, Y., Cao, F., Liu, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Radiation-induced+cell+death+and+its+mechanisms.">Radiation-induced cell death and its mechanisms.</a> Health Physics. 123 (5), 376-386 (2022).</li><li>Roederer, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+genetic+architecture+of+the+human+immune+system:+a+bioresource+for+autoimmunity+and+disease+pathogenesis.">The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis.</a> Cell. 161 (2), 387-403 (2015).</li><li>Bankoglu, E. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effect+of+cryopreservation+on+DNA+damage+and+DNA+repair+activity+in+human+blood+samples+in+the+comet+assay.">Effect of cryopreservation on DNA damage and DNA repair activity in human blood samples in the comet assay.</a> Archives of Toxicology. 95, 1831-1841 (2021).</li><li>Zijno, A., Saini, F., Crebelli, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Suitability+of+cryopreserved+isolated+lymphocytes+for+the+analysis+of+micronuclei+with+the+cytokinesis-block+method.">Suitability of cryopreserved isolated lymphocytes for the analysis of micronuclei with the cytokinesis-block method.</a> Mutagenesis. 22, 311-315 (2007).</li><li>Sioen, S., Cloet, K., Vral, A., Baeyens, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+cytokinesis-block+micronucleus+assay+on+human+isolated+fresh+and+cryopreserved+peripheral+blood+mononuclear+cells.">The cytokinesis-block micronucleus assay on human isolated fresh and cryopreserved peripheral blood mononuclear cells.</a> Journal of Personalized Medicine. 10 (3), 125 (2020).</li><li>Cheng, L., Wang, L. E., Spitz, M. R., Wei, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cryopreserving+whole+blood+for+functional+assays+using+viable+lymphocytes+in+molecular+epidemiology+studies.">Cryopreserving whole blood for functional assays using viable lymphocytes in molecular epidemiology studies.</a> Cancer Letters. 166 (2), 155-163 (2001).</li><li>Beyls, E., Baeyens, A., Vral, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+cytokinesis-block+micronucleus+assay+for+cryopreserved+whole+blood.">The cytokinesis-block micronucleus assay for cryopreserved whole blood.</a> International Journal of Radiation Biology. 97 (9), 1252-1260 (2021).</li><li>Fenech, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cytokinesis-block+micronucleus+cytome+assay.">Cytokinesis-block micronucleus cytome assay.</a> Nature Protocols. 2 (5), 1084-1104 (2007).</li><li>Ramachandran, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Optimal+thawing+of+cryopreserved+peripheral+blood+mononuclear+cells+for+use+in+high-throughput+human+immune+monitoring+studies.">Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies.</a> Cells. 1 (3), 313-324 (2012).</li><li>H&#248;nge, B. L., Petersen, M. S., Olesen, R., M&#248;ller, B. K., Erikstrup, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Optimizing+recovery+of+frozen+human+peripheral+blood+mononuclear+cells+for+flow+cytometry.">Optimizing recovery of frozen human peripheral blood mononuclear cells for flow cytometry.</a> PLoS One. 12 (11), e0187440-e0187517 (2017).</li><li>Alam, I., Goldeck, D., Larbi, A., Pawelec, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Flow+cytometric+lymphocyte+subset+analysis+using+material+from+frozen+whole+blood.">Flow cytometric lymphocyte subset analysis using material from frozen whole blood.</a> Journal of Immunoassay and Immunochemistry. 33 (2), 128-139 (2012).</li><li>Langenski&#246;ld, C., Mellgren, K., Abrahamsson, J., Bemark, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Determination+of+blood+cell+subtype+concentrations+from+frozen+whole+blood+samples+using+TruCount+beads.">Determination of blood cell subtype concentrations from frozen whole blood samples using TruCount beads.</a> Cytometry Part B: Clinical Cytometry. 94B, 660-666 (2018).</li><li>Braudeau, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+easy+and+reliable+whole+blood+freezing+method+for+flow+cytometry+immuno-phenotyping+and+functional+analyses.">An easy and reliable whole blood freezing method for flow cytometry immuno-phenotyping and functional analyses.</a> Cytometry Part B: Clinical Cytometry. 100 (6), 652-665 (2021).</li><li>Thierens, H., Vral, A., De Ridder, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Biological+dosimetry+using+the+micronucleus+assay+for+lymphocytes:+interindividual+differences+in+dose+response.">Biological dosimetry using the micronucleus assay for lymphocytes: interindividual differences in dose response.</a> Health Physics. 61 (5), 623-630 (1991).</li><li>Vral, A., Fenech, M., Thierens, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+micronucleus+assay+as+a+biological+dosimeter+of+in+vivo+ionising+radiation+exposure.">The micronucleus assay as a biological dosimeter of in vivo ionising radiation exposure.</a> Mutagenesis. 26 (1), 11-17 (2011).</li><li>Vral, A., Thierens, H., Baeyens, A., De Ridder, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+micronucleus+and+G2-phase+assays+for+human+blood+lymphocytes+as+biomarkers+of+individual+sensitivity+to+ionizing+radiation:+limitations+imposed+by+intraindividual+variability.">The micronucleus and G2-phase assays for human blood lymphocytes as biomarkers of individual sensitivity to ionizing radiation: limitations imposed by intraindividual variability.</a> Radiation Research. 157 (4), 472-477 (2002).</li><li>Pajic, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inter-individual+variability+in+the+response+of+human+peripheral+blood+lymphocytes+to+ionizing+radiation:+comparison+of+the+dicentric+and+micronucleus+assays.">Inter-individual variability in the response of human peripheral blood lymphocytes to ionizing radiation: comparison of the dicentric and micronucleus assays.</a> Radiation and Environmental Biophysics. 54, 317-325 (2015).</li><li>Fenech, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intra-+and+inter-laboratory+variation+in+the+scoring+of+micronuclei+and+nucleoplasmic+bridges+in+binucleated+human+lymphocytes:+results+of+an+international+slide-scoring+exercise+by+the+HUMN+project.">Intra- and inter-laboratory variation in the scoring of micronuclei and nucleoplasmic bridges in binucleated human lymphocytes: results of an international slide-scoring exercise by the HUMN project.</a> Mutation Research. 534 (1-2), 45-64 (2003).</li><li>Miszczyk, J., Rawoj&#263;, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effects+of+culturing+technique+on+human+peripheral+blood+lymphocytes+response+to+proton+and+X-ray+radiation.">Effects of culturing technique on human peripheral blood lymphocytes response to proton and X-ray radiation.</a> International Journal of Radiation Biology. 96 (4), 424-433 (2020).</li></ol>

The authors have no conflicts of interest to declare.

The modified protocol for the application of the CBMN assay is a relatively easy and convenient way to store blood samples in bulk. The procedure outlines all the minute but important details that need to be taken care of during cryopreservation and the CBMN assay. Other lab protocols normally use 10% DMSO in the freezing mixture, while our freezing mixture contains 20% DMSO along with 80% FCS7. As this freezing mixture is added in equal volumes to the whole blood sample, the final concentration is also 10% DMSO. To improve the cell survival rate and stimulate cell division, we add 1% sodium pyruvate and 0.1% beta-mercaptoethanol to the complete culture medium (cRPMI). This is in accordance with the cell-culture protocol established by our research group6,8. 
Although the problem of cell clumping while thawing could not be resolved completely in this protocol, cell segregation was better than the other conventional protocols. Instead of consistent, abrupt addition of culture media to recover cells post thawing, we obtained better results when prewarmed PBS (37 &#176;C) was added dropwise during the washing steps. This improvement helps in reducing cellular stress and minimizes clumping with a proven high recovery of cells. Furthermore, no clear difference in cell viability could be observed when PBS was used over RPMI. It has been validated by the group that the length of the cryopreservation period (up to 1 year) will not affect MN yields, both in irradiated and non-irradiated samples6,8. Studies suggest that good cell viability and proliferation of PBMCs can be achieved with gradual freezing at low temperatures (liquid nitrogen), followed by gradual addition of prewarmed medium while thawing10,11. Researchers have shown that the sub-populations of T-lymphocytes in thawed whole blood are comparable to those observed in thawed PBMCs12. Further, it is proven that cell subtypes recovered from cryopreserved whole blood samples are similar to those observed in fresh whole blood samples13,14. 
If we examine the indicative results obtained in the report, we see that the linear quadratic increase with dose (Figure 3) is in agreement with other literature reports on Linear energy transfer (LET)-induced micronuclei15,16. The variability in MN yields observed in the cryopreserved whole blood samples (Table 1) are in range with the one reported for fresh whole blood cultures8,17,18. The protocol described in detail here was validated on fresh and cryopreserved whole blood of 20 healthy volunteers8. The nuclear division index (NDI), which is an important parameter of cell proliferation observed in that report8 was in agreement with the one suggested for fresh whole blood19,20. Taken together, this optimized protocol of cryopreservation of whole blood and modified micronucleus assay provides a better cell yield and hence, adaptation of this protocol is recommended for radiosensitivity assessments. Since the reproducibility of the protocol has already been validated8, it is suggested to have applicability in large-scale and multi-center studies.

Ever since its discovery, the use of ionizing radiation (IR) has been a matter of debate among researchers because of its adverse effects on living beings. The detrimental effect is usually manifested by DNA damage such as double-stranded breaks (DSBs), and the failure to repair these DSBs leads to chromosomal aberrations and mutations, which are important hallmarks of cancer1,2. Such chromosomal aberrations can be examined by cytogenic assays such as the cytokinesis-block micronucleus (CBMN) assay. Micronuclei are lagging chromosomal fragments that cannot be incorporated into daughter nuclei and hence, are left behind during mitosis.
CBMN is a commonly used, reliable cytogenetic technique to assess chromosomal damage in individuals exposed to in vivo or in vitro ionizing radiation. Either fresh whole blood or isolated peripheral blood mononuclear cells (PBMCs) can be used in the CBMN assay. Fresh whole blood is mostly the biological material of choice since the isolation and processing of PBMCs can be time-consuming and is accompanied by a loss of serum plasma that acts as the supporting medium for cell survival and growth. To achieve a good binucleated cell yield, fresh whole blood should be processed immediately after collection. However, the need for immediate processing can be logistically challenging during time constraints. Moreover, when many samples are supposed to be acquired over an extended period or collected at points away from the processing centers, storage of fresh blood samples can be a limiting factor3,4.
Further, to allow repeated MN analysis in the same individual/patient, freezing of blood samples would be beneficial. One way to store lymphocytes for later application of the CBMN assay is by freezing isolated PBMCs5,6. This technique, however, requires several processing steps before the PBMCs can be frozen. Therefore, cryopreservation of whole blood would represent a simple and time-efficient alternative to the cryopreservation of isolated PBMCs. Little information is available concerning the use of frozen whole blood for cytogenetic assays or assays that require the proliferation of lymphocytes. Only one paper reports the use of cryopreserved whole blood for metaphase analysis7.
As cryopreservation of whole blood would offer many advantages in the field of biomonitoring, biodosimetry, and radiosensitivity assessment, our group optimized a cryopreservation protocol for whole blood that allows the application of the CBMN assay8. We demonstrated that lymphocytes present in cryopreserved whole blood cultures retain their genomic integrity and proliferation capacity for at least 1 year. In this methods paper, we describe in detail the cryopreservation procedure and CBMN assay protocol, which was optimized by Beyls et al.8, and report findings obtained for frozen blood samples of 30 healthy individuals. For the CBMN assay, the blood cultures were irradiated in vitro with doses of 0.5, 1, and 2 Gy to assess the MN response in lymphocytes of cryopreserved whole blood samples.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>15 mL centrifuge tubes</td>
			<td>Greiner</td>
			<td>188271</td>
			<td></td>
		</tr>
		<tr>
			<td>24-well cell suspension plate&#160;</td>
			<td>VWR</td>
			<td>734-2779</td>
			<td></td>
		</tr>
		<tr>
			<td>96% alcohol</td>
			<td>ChemLab</td>
			<td>CL00.1807.2500</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetic acid</td>
			<td>Merck life science</td>
			<td>8,18,75,52,500</td>
			<td></td>
		</tr>
		<tr>
			<td>Acridine orange</td>
			<td>Merck life science</td>
			<td>235474-5g</td>
			<td></td>
		</tr>
		<tr>
			<td>CaCl2</td>
			<td>Merck life science</td>
			<td>C5670-100g</td>
			<td></td>
		</tr>
		<tr>
			<td>cover slips</td>
			<td>VWR</td>
			<td>631-1365</td>
			<td>22 x 50</td>
		</tr>
		<tr>
			<td>Cryobox (Mr.Frosty)</td>
			<td>Nalgene, Sigma Aldrich</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Cryovials 2ml</td>
			<td>Novolab</td>
			<td>A04573</td>
			<td></td>
		</tr>
		<tr>
			<td>Cytochalsin B&#160;</td>
			<td>Merck life science</td>
			<td>C6762-10</td>
			<td>10 mg</td>
		</tr>
		<tr>
			<td>Dimethyl sulphoxide (DMSO)</td>
			<td>Merck life science</td>
			<td>D4540-500ml</td>
			<td></td>
		</tr>
		<tr>
			<td>Fetal calf serum (FCS)</td>
			<td>Thermo Fischer scientific</td>
			<td>10270-106</td>
			<td></td>
		</tr>
		<tr>
			<td>Fixative 1</td>
			<td></td>
			<td></td>
			<td>Methanol/acetic acid/ringer in a ratio of 4:1:5</td>
		</tr>
		<tr>
			<td>Fixative 2</td>
			<td></td>
			<td></td>
			<td>Methanol/acetic acid in a ratio of 4:1</td>
		</tr>
		<tr>
			<td>GURR buffer</td>
			<td>Thermo Fischer scientific</td>
			<td>10582013</td>
			<td>phosphate buffer (pH 6.8)</td>
		</tr>
		<tr>
			<td>KCl</td>
			<td>Merck life science</td>
			<td>1,04,93,60,250</td>
			<td>75 mM</td>
		</tr>
		<tr>
			<td>KH2PO4</td>
			<td>Merck life science</td>
			<td>1,04,87,30,250</td>
			<td></td>
		</tr>
		<tr>
			<td>Li-heparin tubes</td>
			<td>BD Life sciences</td>
			<td>367526-LH170 I.U.</td>
			<td>BD Vacutainer</td>
		</tr>
		<tr>
			<td>Methanol</td>
			<td>fisher scinetific</td>
			<td>M/4000/17</td>
			<td></td>
		</tr>
		<tr>
			<td>Na2HPO2</td>
			<td>Merck life science</td>
			<td>10,65,80,500</td>
			<td></td>
		</tr>
		<tr>
			<td>NaCl</td>
			<td>Merck life science</td>
			<td>S7653-1kg</td>
			<td></td>
		</tr>
		<tr>
			<td>Object slides</td>
			<td>VWR</td>
			<td>MENZAA00000112E04</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin/Streptomycin</td>
			<td>Thermo Fischer scientific</td>
			<td>15140-122</td>
			<td>10,000 U/mL + 10,000 &#181;g/mL</td>
		</tr>
		<tr>
			<td>Phytohemagglutinin (PHA-M)</td>
			<td>Thermo Fischer scientific</td>
			<td>10576-015</td>
			<td></td>
		</tr>
		<tr>
			<td>Ringer solution</td>
			<td></td>
			<td></td>
			<td>contains NaCl, KCl, CaCl2 dissolved in distilled water</td>
		</tr>
		<tr>
			<td>RPMI-1640</td>
			<td>Thermo Fischer scientific</td>
			<td>52400041</td>
			<td></td>
		</tr>
		<tr>
			<td>Silicon rubber adhesive sealent</td>
			<td>collall</td>
			<td>CF-100</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium pyruvate</td>
			<td>Thermo Fischer scientific</td>
			<td>11360039</td>
			<td></td>
		</tr>
		<tr>
			<td>Sterile warm PBS (37 &#176;C)</td>
			<td></td>
			<td></td>
			<td>contains NaCl,&#160; Na2HPO2, KH2PO4 dissolved in distilled water</td>
		</tr>
		<tr>
			<td>&#946;-mercaptoethanol</td>
			<td>Thermo Fischer scientific</td>
			<td>31350-010</td>
			<td></td>
		</tr>
	</tbody>
</table>

the micronucleus assay on cryopreserved whole blood

The in vitro cytokinesis-block micronucleus (CBMN) assay is a widely used technique in radiobiology research, biological dosimetry, genotoxicity studies, and in vitro radiosensitivity testing. This cytogenetic method is based on the detection of micronuclei in binucleated cells resulting from chromosomal fragments lagging during cell division. Fresh whole blood samples are the most preferred sample type for the CBMN assay. However, the disadvantages of working with fresh blood samples include immediate processing after blood collection and the limited number of repeated analyses that can be performed without extra blood sampling. 
As the need for fresh blood samples can be logistically challenging, CBMN assay on cryopreserved whole blood samples would be of great advantage, especially in large-scale patient studies. This paper describes a protocol to freeze whole blood samples and to perform the CBMN assay on these frozen blood samples. Blood samples from healthy volunteers have been frozen and thawed at different time points and then, subjected to a modified micronucleus assay protocol. The results demonstrate that this optimized procedure allows the performance of the CBMN assay on frozen blood samples. The described cryopreservation protocol may also be very useful for other cytogenetic assays and a variety of functional assays requiring proliferating lymphocytes.

To validate the reproducibility of the protocol, we performed the MN assay on cryopreserved blood samples of 30 healthy volunteers aged between 17 and 65 years. The mean age of the group is 35 years. The cryopreservation time ranged from 1 week to 154 weeks. After exposing the whole blood cell culture to different radiation doses (0.5, 1, and 2 Gy), the micronuclei yield in 1,000 BN cells was examined under a microscope. Nicely rounded binucleated cells (as can be seen in Figure 2) indicate a successful retrieval of healthy viable cells from cryopreserved whole blood samples. Of note, the radiation response of lymphocytes remained stable after long-term storage at ultra-low temperatures (liquid nitrogen). This observation is in line with the response expected from fresh blood samples.
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/65855/65855fig02v2.jpg" /> 
Figure 2: Micronuclei as observed in binucleated cells retrieved from a frozen whole blood sample that was cryopreserved 1 year ago. (A) Magnification 200x, (B) Magnification 400x; Arrows pointing to the MNs. Scale bar = 50 &#181;m. <a href="https://www.jove.com/files/ftp_upload/65855/65855fig02large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
With increased doses of radiation (0.5, 1, and 2 Gy), a linear-quadratic increase in micronucleus yield was observed (Table 1 and Figure 3). The MN yields in sham irradiated control samples (0 Gy) represent the background MN yields that are mainly the result of lagging chromosomes.
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Dose (Gy)</td>
			<td>0</td>
			<td>0.5</td>
			<td>1</td>
			<td>2</td>
		</tr>
		<tr>
			<td>Average</td>
			<td>18</td>
			<td>107</td>
			<td>247</td>
			<td>601</td>
		</tr>
		<tr>
			<td>SD</td>
			<td>10.8</td>
			<td>23.9</td>
			<td>53.3</td>
			<td>101.1</td>
		</tr>
		<tr>
			<td>CV (%)</td>
			<td>59.9</td>
			<td>22.3</td>
			<td>21.6</td>
			<td>16.8</td>
		</tr>
		<tr>
			<td>Range</td>
			<td>5-41&#160;&#160;</td>
			<td>62-140</td>
			<td>139-324</td>
			<td>395-755</td>
		</tr>
	</tbody>
</table>
Table 1: Range and coefficient of variation along with average MN yield, as observed in cryopreserved whole blood samples of 30 healthy donors, indicative of inter-individual variability. Abbreviations: CV = coefficient of variation; SD = standard deviation.
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/65855/65855fig03.jpg" /> 
Figure 3: Micronuclei yields as observed in control and irradiated cryopreserved whole blood samples of 30 donors. Cryopreservation periods ranged from 1 week to 154 weeks. Scatter plot graph shows&#160;individual values. Lines in clusters represent the Mean &#177; SD of the group. Abbreviations: MN = micronuclei; BN = binucleated. <a href="https://www.jove.com/files/ftp_upload/65855/65855fig03large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
To investigate the interindividual variation in the MN yield of persons, the coefficient of variation (CV) was calculated (see Table 1). For radiation-induced MN, a CV &#60; 25% was obtained for all doses (0.5, 1, and 2 Gy), which indicates good reproducibility of the modified protocol.

Watch this Scientific Journal Video about Cryopreservation of Whole Blood Samples for High Throughput Analysis at JoVE.com

Author Spotlight: Cryopreservation of Whole Blood Samples for High Throughput Analysis 

Here we present an optimized protocol for the cytokinesis-block micronucleus assay on cryopreserved whole blood samples. This optimized method of cryopreservation of whole blood for micronucleus analysis is a reliable technique for large-scale sampling and multi-center studies and can be used for other blood-related assays as well.

The Micronucleus Assay on Cryopreserved Whole Blood

The in vitro cytokinesis-block micronucleus (CBMN) assay is a widely used technique in radiobiology research, biological dosimetry, genotoxicity studies, ...

the-micronucleus-assay-on-cryopreserved-whole-blood

Universidad San Sebastian

Research

JoVE Journal

Cancer Research

3.3K Views.  Ghent University. Here we present an optimized protocol for the cytokinesis-block micronucleus assay on cryopreserved whole blood samples. This optimized method of cryopreservation of whole blood for micronucleus analysis is a reliable technique for large-scale sampling and multi-center studies and can be used for other blood-related assays as well.

Video: Author Spotlight: Cryopreservation of Whole Blood Samples for High Throughput Analysis 

Capture and Release of Viable Circulating Tumor Cells from Blood

We demonstrate a method for size based capture of viable circulating tumor cell (CTC) from whole blood, along with the release of these cells from chip for downstream analysis and/or culture. The strategy employs the use of a novel Parylene C membrane slot pore microfilter to capture CTC and a coating of poly (N-iso-propylacrylamide) (PIPAAm) for thermoresponsive viable release of the captured CTC. The capture of live cells is enabled by leveraging the design of a slot pore geometry with specific dimensions to reduce the shear stress typically associated with the filtration process. While the microfilter exhibits a high capture efficiency, the release of these cells is non-trivial. Typically, only a small percentage of cells are released when techniques such as reverse flow or cell scraping are used. The strong adhesion of these epithelial cancer cells to the Parylene C membrane is attributable to non-specific electrostatic interaction. To counteract this effect, we employed the use of PIPAAm coating and exploited its thermal responsive interfacial properties to release the cells from the filter. Blood is first filtered at room temperature. Below 32 &#176;C, PIPAAm is hydrophilic. Thereafter, the filter is placed in either culture media or a buffer maintained at 37 &#176;C, which results in the PIPAAm turning hydrophobic, and subsequently releasing the electrostatically bound cells.

A protocol to utilize a poly(N-iso-propylacrylamide) (PIPAAm) coated microfilter for effective capture and thermoresponsive release of viable circulating tumor cells (CTC) is presented. This method allows capture of CTC from patients&#39; blood and subsequent release of viable CTC for downstream off-chip culture, analyses and characterization.

We demonstrate a method for size based capture of viable circulating tumor cell (CTC) from whole blood, along with the release of these cells from chip ...

The Drosophila Imaginal Disc Tumor Model: Visualization and Quantification of Gene Expression and Tumor Invasiveness Using Genetic Mosaics

Drosophila melanogaster has emerged as a powerful experimental system for functional and mechanistic studies of tumor development and progression in the context of a whole organism. Sophisticated techniques to generate genetic mosaics facilitate induction of visually marked, genetically defined clones surrounded by normal tissue. The clones can be analyzed through diverse molecular, cellular and omics approaches. This study describes how to generate fluorescently labeled clonal tumors of varying malignancy in the eye/antennal imaginal discs (EAD) of Drosophila larvae using the Mosaic Analysis with a Repressible Cell Marker (MARCM) technique. It describes procedures how to recover the mosaic EAD and brain from the larvae and how to process them for simultaneous imaging of fluorescent transgenic reporters and antibody staining. To facilitate molecular characterization of the mosaic tissue, we describe a protocol for isolation of total RNA from the EAD. The dissection procedure is suitable to recover EAD and brains from any larval stage. The fixation and staining protocol for imaginal discs works with a number of transgenic reporters and antibodies that recognize Drosophila proteins. The protocol for RNA isolation can be applied to various larval organs, whole larvae, and adult flies. Total RNA can be used for profiling of gene expression changes using candidate or genome-wide approaches. Finally, we detail a method for quantifying invasiveness of the clonal tumors. Although this method has limited use, its underlying concept is broadly applicable to other quantitative studies where cognitive bias must be avoided.

The Drosophila Imaginal Disc Tumor Model: Visualization and Quantification of Gene Expression and Tumor Invasiveness Using Genetic Mosaics

This protocol demonstrates how to generate fluorescently marked, genetically defined clonal tumors in the Drosophila eye/antennal imaginal discs (EAD). It describes how to dissect the EAD and brain from the third instar larvae and how to process them to visualize and quantify gene expression changes and tumor invasiveness.

Drosophila melanogaster has emerged as a powerful experimental system for functional and mechanistic studies of tumor development and progression in the ...

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

siRNA and shRNA-mediated knock down (KD) methods of regulating gene expression are invaluable tools for understanding gene and protein function. However, in the case that the KD of the protein of interest has a lethal effect on cells or the anticipated effect of the KD is time-dependent, unconditional KD methods are not appropriate. Conditional systems are more suitable in these cases and have been the subject of much interest. These include Ecdysone-inducible overexpression systems, Cytochrome P-450 induction system1, and the tetracycline regulated gene expression systems. 
The tetracycline regulated gene expression system enables reversible control over protein expression by induction of shRNA expression in the presence of tetracycline. In this protocol, we present an experimental design using functional Tet-ON system in human cancer cell lines for conditional regulation of gene expression. We then demonstrate the use of this system in the study of tumor cell-monocyte interaction.

This protocol serves as a scheme for setting up a functional Tet-ON system in cancer cell lines and its subsequent use, in particular for studying the role of tumor cell-derived proteins in recruitment of monocytes/macrophages to the tumor microenvironment.

siRNA and shRNA-mediated knock down (KD) methods of regulating gene expression are invaluable tools for understanding gene and protein function. However, ...

Evaluation of the Cell Invasion and Migration Process: A Comparison of the Video Microscope-based Scratch Wound Assay and the Boyden Chamber Assay

The invasion and migration abilities of tumor cells are main contributors to cancer progression and recurrence. Many studies have explored the migration and invasion abilities to understand how cancer cells disseminate, with the aim of developing new treatment strategies. Analysis of the cellular and molecular basis of these abilities has led to the characterization of cell mobility and the physicochemical properties of the cytoskeleton and cellular microenvironment. For many years, the Boyden chamber assay and the scratch wound assay have been the standard techniques to study cell invasion and migration. However, these two techniques have limitations. The Boyden chamber assay is difficult and time consuming, and the scratch wound assay has low reproducibility. Development of modern technologies, especially in microscopy, has increased the reproducibility of the scratch wound assay. Using powerful analysis systems, an &#34;in-incubator&#34; video microscope can be used to provide automatic and real-time analysis of cell migration and invasion. The aim of this paper is to report and compare the two assays used to study cell invasion and migration: the Boyden chamber assay and an optimized in vitro video microscope-based scratch wound assay.

This study reports two different methods for the analysis of cell invasion and migration: the Boyden chamber assay and the in vitro video microscope-based wound-healing assay. The protocols for these two experiments are described, and their benefits and disadvantages are compared.

The invasion and migration abilities of tumor cells are main contributors to cancer progression and recurrence. Many studies have explored the migration ...

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Integrated PET/MRI is a hybrid imaging technique enabling clinicians to acquire diagnostic images for tumor assessment and treatment monitoring with both high soft tissue contrast and added metabolic information. Integrated PET/MRI has shown to be valuable in the clinical setting and has many promising future applications. The protocol presented here will provide step-by-step instructions for the acquisition of whole-body 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/MRI data in children with cancer. It also provides instructions on how to combine a whole-body staging scan with a local tumor scan for evaluation of the primary tumor. The focus of this protocol is to be both comprehensive and time-efficient, which are two ubiquitous needs for clinical applications. This protocol was originally developed for children above 6 years, or old enough to comply with breath-hold instructions, but can also be applied to patients under general anesthesia. Similarly, this protocol can be modified to fit institutional preferences in terms of choice of MRI pulse sequences for both the whole-body scan and local tumor assessment.

This article provides comprehensive step-by-step instructions for the acquisition of whole-body 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/MRI scans for cancer staging of pediatric patients. The protocol was developed for children above 6 years, or old enough to comply with breath-hold instructions, but can be used for general anesthesia patients as well.

Integrated PET/MRI is a hybrid imaging technique enabling clinicians to acquire diagnostic images for tumor assessment and treatment monitoring with both ...

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, a small population of cells does not respond to TKI treatment, resulting in minimal residual disease (MRD); even the most potent TKIs fail to eradicate these cells. These MRD cells serve as a reservoir to develop resistance to therapy. Why TKI treatment is ineffective against MRD cells is not known. Growth factor signaling is implicated in supporting the survival of MRD cells during TKI treatment, but a mechanistic understanding is lacking. Recent studies demonstrated that an elevated c-Fos and Dusp1 expression as a result of convergent oncogenic and growth factor signaling in MRD cells mediate TKI resistance. The genetic and chemical inhibition of c-Fos and Dusp1 renders CML exquisitely sensitive to TKIs and cures CML in both genetic and humanized mouse models. We identified these target genes using multiple microarrays from TKI-sensitive and -resistant cells. Here, we provide methods for target validation using in vitro and in vivo mouse models. These methods can easily be applied to any target for genetic validation and therapeutic development.

Here, we describe protocols for the genetic and chemical validation of c-Fos and Dusp1 as a drug target in leukemia using in vitro and in vivo genetic and humanized mouse models. This method can be applied to any target for genetic validation and therapeutic development.

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, ...

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Gene perturbation studies have been extensively used to investigate the role of individual genes in AML pathogenesis. For achieving complete gene disruption, many of these studies have made use of complex gene knockout models. While these studies with knockout mice offer an elegant and time-tested system for investigating genotype-to-phenotype relationships, a rapid and scalable method for assessing candidate genes that play a role in AML cell proliferation or survival in AML models will help accelerate the parallel interrogation of multiple candidate genes. Recent advances in genome-editing technologies have dramatically enhanced our ability to perform genetic perturbations at an unprecedented scale. One such system of genome editing is the CRISPR-Cas9-based method that can be used to make rapid and efficacious alterations in the target cell genome. The ease and scalability of CRISPR/Cas9-mediated gene-deletion makes it one of the most attractive techniques for the interrogation of a large number of genes in phenotypic assays. Here, we present a simple assay using CRISPR/Cas9 mediated gene-disruption combined with high-throughput flow-cytometry-based competition assays to investigate the role of genes that may play an important role in the proliferation or survival of human and murine AML cell lines.

This manuscript describes a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) CRISPR-Cas9-based method for simple and expeditious investigation of the role of multiple candidate genes in Acute Myeloid Leukemia (AML) cell proliferation in parallel. This technique is scalable and can be applied in other cancer cell lines as well.

Gene perturbation studies have been extensively used to investigate the role of individual genes in AML pathogenesis. For achieving complete gene ...

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Potentiation of the tumor-killing ability of CD8+ T cells in tumors, along with their efficient tumor infiltration, is a key element of successful immunotherapies. Several studies have indicated that tumor infiltrating myeloid cells (e.g., myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs)) suppress cytotoxicity of CD8+ T cells in the tumor microenvironment, and that targeting these regulatory myeloid cells can improve immunotherapies. Here, we present an in vitro assay system to evaluate immune suppressive effects of monocytic-MDSCs and TAMs on the tumor-killing ability of CD8+ T cells. To this end, we first cultured na&#239;ve splenic CD8+ T cells with anti-CD3/CD28 activating antibodies in the presence or absence of suppressor cells, and then co-cultured the pre-activated T cells with target cancer cells in the presence of a fluorogenic caspase-3 substrate. Fluorescence from the substrate in cancer cells was detected by real-time fluorescence microscopy as an indicator of T-cell induced tumor cell apoptosis. In this assay, we can successfully detect the increase of tumor cell apoptosis by CD8+ T cells and its suppression by pre-culture with TAMs or MDSCs. This functional assay is useful for investigating CD8+ T cell suppression mechanisms by regulatory myeloid cells and identifying druggable targets to overcome it via high throughput screening.

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

We describe here a protocol to investigate cytotoxicity of pre-activated CD8+ T cells against cancer cells by detecting apoptotic cancer cells via real-time microscopy. This protocol can investigate mechanisms behind myeloid cell-induced T cell suppression and evaluate compounds aimed at replenishing T cells via blockade of immune suppressive myeloid cells.

Potentiation of the tumor-killing ability of CD8+ T cells in tumors, along with their efficient tumor infiltration, is a key element of successful ...

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

We present a flow cytometric approach for analyzing mitochondrial ROS in various live bone marrow (BM)-derived stem and progenitor cell populations from healthy mice as well as mice with AML driven by MLL-AF9. Specifically, we describe a two-step cell staining process, whereby healthy or leukemia BM cells are first stained with a fluorogenic dye that detects mitochondrial superoxides, followed by staining with fluorochrome-linked monoclonal antibodies that are used to distinguish various healthy and malignant hematopoietic progenitor populations. We also provide a strategy for acquiring and analyzing the samples by flow cytometry. The entire protocol can be carried out in a timeframe as short as 3-4 h. We also highlight the key variables to consider as well as the advantages and limitations of monitoring ROS production in the mitochondrial compartment of live hematopoietic and leukemia stem and progenitor subpopulations using fluorogenic dyes by flow cytometry. Furthermore, we present data that mitochondrial ROS abundance varies among distinct healthy HSPC sub-populations and leukemia progenitors and discuss the possible applications of this technique in hematologic research.

We describe a method for using multiparameter flow cytometry to detect mitochondrial reactive oxygen species (ROS) in murine healthy hematopoietic stem and progenitor cells (HSPCs) and leukemia cells from a mouse model of acute myeloid leukemia (AML) driven by MLL-AF9.

We present a flow cytometric approach for analyzing mitochondrial ROS in various live bone marrow (BM)-derived stem and progenitor cell populations from ...

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Identifying mutations in tumors of cancer patients is a very important step in disease management. These mutations serve as biomarkers for tumor diagnosis as well as for the treatment selection and its response in cancer patients. The current gold standard method for detecting tumor mutations involves a genetic test of tumor DNA by means of tumor biopsies. However, this invasive method is difficult to be performed repeatedly as a follow-up test of the tumor mutational repertoire. Liquid biopsy is a new and emerging technique for detecting tumor mutations as an easy-to-use and non-invasive biopsy approach.
Cancer cells multiply rapidly. In parallel, numerous cancer cells undergo apoptosis. Debris from these cells are released into a patient&#8217;s circulatory system, together with finely fragmented DNA pieces, called cell-free DNA (cfDNA) fragments, which carry tumor DNA mutations. Therefore, for identifying cfDNA based biomarkers using liquid biopsy technique, blood samples are collected from the cancer patients, followed by the separation of plasma and buffy coat. Next, plasma is processed for the isolation of cfDNA, and the respective buffy coat is processed for the isolation of a patient&#39;s genomic DNA. Both nucleic acid samples are then checked for their quantity and quality; and analyzed for mutations using next-generation sequencing (NGS) techniques.
In this manuscript, we present a detailed protocol for liquid biopsy, including blood collection, plasma, and buffy coat separation, cfDNA and germline DNA extraction, quantification of cfDNA or germline DNA, and cfDNA fragment enrichment analysis.

In this paper we present a detailed protocol for non-invasive liquid biopsy technique, including blood collection, plasma and buffy coat separation, cfDNA and germline DNA extraction, quantification of cfDNA or germline DNA, and cfDNA fragment enrichment analysis.

Identifying mutations in tumors of cancer patients is a very important step in disease management. These mutations serve as biomarkers for tumor diagnosis ...